Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Explore what the three stages of financial planning are to better understand your financial journey. Start your planning process now.
21,355 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
A former Central Colorado parcel near Salida is being developed into a 55-acre, 106-home 3D-printed community, testin...
NuScale Power faced a sharp February sell-off as project delays, funding needs, and analyst downgrades weighed on the...
Federal regulators are probing George Santos over Kalshi trades linked to his State of the Union attendance, a high p...
Congress passed a sweeping housing package that has now become law, promising to streamline permitting, expand financ...
A hedge fund just trimmed a large stake in NCR Voyix, but does that spell change for ordinary investors? This guide b...
SpaceX is eyeing a historic IPO. This guide explains the spacex date: what investors should watch, how pricing could ...
When biotech headlines hit, stocks can swing quickly. Here’s a grounded look at why stock skyrocketed today for Q32 B...
Oklo rose 5% and NuScale Power gained 3% in early trading as investors renewed interest in nuclear energy stocks amid...
A high-profile former AI czar challenges Sanders’ 50% government stake plan for AI firms, warning that nationalizatio...
A trading halt and a sharp drop put Lucid in the spotlight, but the company pushed back on bankruptcy chatter. This g...
Markets move on news that the U.S. DEA has designated Colombia's president as a priority target in an ongoing probe. ...